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COMMENTARY
Chemotherapy of Multiple Myeloma:
Melphalan—40 Years Old and Still Going Strong
It has been 40 years since the activity of melphalan in
multiple myeloma was ﬁrst reported [1]. Since that time it has
been the subject of countless clinical trials designed to deter-
mine the optimal way to use it in the treatment of patients.
Unfortunately only very few of these were randomized phase III
clinical trials, and the message from the others has largely been
lost with the passage of time. Most of the phase III trials
examined standard doses of oral melphalan, compared with
various combinations of melphalan with other chemotherapeu-
tic agents. An overview of 18 of these trials that treated 3814
patients was reviewed as a meta-analysis 10 years ago, and the
investigators concluded that the combinations did not appear to
offer signiﬁcant advantages over melphalan alone [2]. Looking
back, we can see that the differences were small, and none of the
treatment arms were satisfactory. These regimens have collec-
tively been called “standard chemotherapy” or “conventional
chemotherapy,” although both of these terms now seem out-
dated, as we now have new standards and conventions. We
cannot even call them “low-dose chemotherapy” regimens. The
dose of melphalan in a common oral regimen is 10 mg/m2 daily
for 4 days, repeated monthly. As patients are treated about a year
on average, this works out to a total dose of melphalan of 480
mg/m2, signiﬁcantly higher then the single 200 mg/m2 recom-
mended for patients undergoing autologous stem cell transplan-
tation. These regimens could appropriately be called “low-dose–
intensity chemotherapy” or “non-myeloablative chemotherapy,”
although for the time being it is probably easier to stick to the
old names, realizing that they may truly belong to another
generation.
In contrast to this experience in 18 trials with 3814 patients
with standard chemotherapy, the evidence-based review in this
issue of Biology of Blood and Marrow Transplantation [3] examines
the role of high-dose chemotherapy with hematopoietic stem
cell transplantation in multiple myeloma. In this exhaustive
summary that includes almost 200 references it is remarkable
that there is only 1 prospective randomized phase III clinical
trial comparing this treatment to standard chemotherapy, with
only 100 patients in each arm [4]. Hopefully the results of other
phase III trials, including the SWOG/ECOG/CALGB study,
will be available soon. In the relative absence of phase III trials,
the evidence-based review takes on special importance, and we
need to begin weighing secondary forms of evidence. Among
these, the study from the Nordic Myeloma Study group deserves
special emphasis [5]. This was a large prospective population-
based study that used retrospective controls selected from earlier
studies. In addition to analyzing a large number of patients, the
Group estimates that it recruited over 60% of expected eligible
patients to the trial, hopefully minimizing selection bias. How-
ever, the overriding importance of selection bias cannot be
ignored. Even within this comprehensive, well-designed regis-
tration study the outcomes for patients treated with transplants
varied signiﬁcantly among the 3 participating Scandinavian
countries; differences in outcomes in different countries had
never been observed in any of the earlier or the subsequent
studies. A preliminary analysis of the data suggests that in this
ﬁrst transplant trial the doctors from one of the countries did
not recruit patients as comprehensively, resulting in the exclu-
sion of some of the patients with a good prognosis (Hans E.
Johnsen, personal communication, October 2002).
Originally designed with curative intent, it is now clear that
transplantations have failed to deliver on this promise. From the
randomized study we can conclude that there is a prolongation
in event-free survival from 18 to 27 months, with a roughly
similar prolongation in overall survival [4]. However, continued
follow-up of this and other studies makes it clear that there is no
plateau to the curve, and relapses continue to occur with time.
For this reason it is important to prospectively identify those
patients who achieve lasting beneﬁt from transplants and de-
velop new treatment approaches for those who achieve no or
only transient beneﬁt. Several prognostic factors have been
identiﬁed, with the combination of elevated 2-microglobulin
and ﬂuorescent in situ hybridization deletion 13 recently sug-
gested to stratify patients [6]. In this study the 30% of patients
with both adverse factors had a median survival of only 25
months. More exciting from a pathophysiologic and transla-
tional therapeutic standpoint is the recent report from the same
group [7] that the 80-month survival with 1 or 2 transplants in
patients with t(11;14) was a remarkable 88%, compared with a
dismal 23% for patients with t(4;14). Compared with the only
moderately better survival noted for patients with t(11;14) who
were treated with conventional chemotherapy [8], transplants
may offer a particular advantage to this subset of patients. In
contrast, it is clear that patients with t(4;14) do not do well with
transplant alone, and new or additional therapies are warranted.
We can now begin designing therapies to target the underlying
genetic basis for this difference, for example, inhibiting the
FGFR3 tyrosine kinase with small molecules [9].
In the end we are left with the problem of deciding how to
treat patients today based primarily on published trials that were
designed more then 10 years ago. Although this seems like a
long time, if we look at the historically excruciatingly slow pace
of development of new therapies in multiple myeloma, it is not
so bad. With the recent advent of new drugs, primarily thalid-
omide and its analogs, and the proteasome inhibitor PS-341
[10,11], we have hope that this pace will accelerate and that we
can more quickly ﬁnd ways to incorporate them into the new
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“standard” therapy based on autologous stem cell transplanta-
tion. As is clear from an evidence-based review of the literature,
this will be much easier if patients are treated on prospective,
randomized phase III clinical trials.
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